A 7-Day Losing Streak Has Stryker Stock Down 17%
A seven-day slide has erased billions in value, putting the company’s premium valuation in the spotlight against its fundamentals.
Stryker (SYK) stock has fallen 16.7% over its current losing streak, which has now run for 7 consecutive trading days. The decline has erased about $21 billion from the company’s market value, which now stands at about $106 billion.
This sharp decline is company-specific rather than market-driven, with extended slides of this length remaining exceedingly rare across the S&P 500.
SYK Versus The S&P 500, Streak And Beyond
Here is how SYK stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | SYK | S&P 500 |
|---|---|---|
| 1D | -0.4% | -0.5% |
| 7D (Current Streak) | -16.7% | -1.0% |
| 1M (21D) | -20.4% | -1.5% |
| 3M (63D) | -12.1% | 3.4% |
| YTD 2026 | -21.2% | 11.6% |
| 2025 | -1.5% | 16.4% |
| 2024 | 21.3% | 23.3% |
| 2023 | 23.8% | 24.2% |
The stock’s slide tests a premium valuation against solid fundamentals.
While available reporting shows no definitive catalyst for the sustained drop, the move puts renewed focus on Stryker’s persistent valuation premium over the broader sector. Stryker trades at a price-to-earnings multiple of 28.3, compared to an S&P 500 median of 22.9 and a median of 25.8 for Health Care stocks. Such prolonged drops remain an anomaly across the broader market, with only 8 other S&P 500 stocks currently experiencing losing streaks of seven days or more.
At the same time, the company’s operational metrics appear steady. Revenue over the last twelve months grew 8.5%, just ahead of the S&P 500 median of 8.3%. Its operating margin of 21.7% also stands above the index median of 18.7%, bolstered by a 3-year average revenue growth rate of 9.9% and a free cash flow yield of 4.5%.
A streak is a signal to re-evaluate, not a command to act.
A string of losses like this is information. It tells you that momentum and investor attention have shifted, but it does not provide an instruction. A streak is not a reason to buy or sell a stock on its own.
The disciplined response is to use this moment of focus to check the business against its price. The fundamental and valuation data here is a starting point for that work: does the business performance justify the stock’s price, even after the recent decline?
A slide like this always poses the same follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.
And for anyone who would rather back the theme than one company’s story, a healthcare ETF like XLV holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
One name’s volatility shouldn’t break the plan
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. A disciplined, rules-based allocation helps insulate an overall portfolio from single-stock volatility, regardless of market direction.